All News
Filter News
Found 2,520 articles
-
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
12/12/2023
Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals.
-
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
12/11/2023
Merck & Co. and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157).
-
Odyssey Therapeutics Announces $101 Million Series C Financing
12/5/2023
Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics with the goal of providing transformative medicines for large numbers of patients in need and several of these molecules have the potential to enter the clinic in the next 12 months.
-
Moving RNA Therapeutics Beyond the Liver
12/4/2023
From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain. -
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.
-
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
11/29/2023
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctLNP) delivery system for wholly-owned programs in extrahepatic cell types.
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
11/28/2023
Thermo Fisher Scientific Inc., the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.
-
Pfizer and BioNTech scored a win over Moderna on Tuesday as the European Patent Office decided that a key patent held by the Massachusetts biotech related to its COVID-19 vaccine is invalid.
-
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
11/21/2023
Madrigal Pharmaceuticals, Inc. today announced that Ronald Filippo has been appointed Chief Information Officer.
-
5 Cancer Vaccines to Watch in 2024
11/20/2023
BioSpace takes a deep dive into five investigational therapeutic cancer vaccines that have recently shown efficacy in difficult-to-treat indications. -
Novavax and R.A. Miller Industries receive the 2023 "Tell Award" for their business investments in Switzerland
11/15/2023
Novavax and R.A. Miller Industries, two American companies at the forefront of innovation, have each won a 2023 Tell Award from the Swiss authorities, recognizing their significant foreign direct investment in Switzerland, reports Daniel Bangser, Trade Commissioner of Switzerland.
-
Immatics Announces Third Quarter 2023 Financial Results and Business Update
11/14/2023
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended September 30, 2023.
-
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
11/14/2023
GeoVax Labs, Inc. announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine.
-
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
11/14/2023
Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.
-
The vaccine maker is prepared to cut another $300 million in operating expenses in 2024 to keep the company afloat as it works to get its combination COVID-19/flu vaccine into Phase III.
-
Research associates are always in demand. Check out these top companies currently hiring RAs.
-
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
11/9/2023
Protagonist Therapeutics announced it ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America.
-
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/9/2023
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.
-
Revolution Medicines Completes Acquisition of EQRx
11/9/2023
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced it has closed its acquisition of EQRx, Inc.
-
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
11/9/2023
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.